Cardiff, UK – Thursday 18th October 2012 – EKF Diagnostics, worldwide manufacturer of point-of-care (POC) diagnostic tools, will be introducing two new low cost POC analysers at Medica 2012. The EKF stand (Hall 3 C70) will see the European launch of the new Quo-Lab glycated haemoglobin (HbA1c) analyser for the affordable management of diabetes, as well as a preview of a new strip-based analyser for highly accurate near patient testing of ketosis – the STAT-SiteTM M bHB.
The semi-automated Quo-Lab HbA1c analyser is CE marked and provides highly accurate, affordable and easy-to-use technology for GP surgeries, diabetes clinics and laboratories. HbA1c monitoring is increasingly used in the detection and management of diabetes and Quo-Lab is designed to meet the needs of economies where resources are limited and where diabetes is an increasingly large public health issue. Requiring minimal training and just 4 µL of venous or finger prick blood, the small and lightweight Quo-Lab delivers lab-accurate results within four minutes.
EKF will also be previewing its first strip-based ketone analyser, the STAT-SiteTM M bHB, which promises to take testing for ketoacidosis out of the laboratory and into the emergency room. ß-Hydroxybutyrate (bHB) is the main ketone produced during ketosis and provides a quantitative and accurate assessment of patients displaying symptoms of ketosis.
The launch of STAT SiteTM M bHB follows the recent success of the ß-Hydroxybutyrate (bHB) LiquiColor® Reagent System developed by EKF subsidiary, Stanbio Laboratory. The bHB liquid stable reagent can be used on any open channel analyser and is used by 13 of the USA’s top 25 diabetes and endocrinology hospitals to provide rapid, objective results.
Quo-Lab and STAT SiteTM M bHB will both be demonstrated at Medica 2012 in a series of free mini-seminars on the EKF Diagnostics stand. Visitors to Medica 2012 can book a free seminar place by emailing email@example.com
For more information please visit www.ekfdiagnostics.com
About EKF Diagnostics Holdings plc
The EKF Diagnostics Group is a worldwide IVD business with expertise across the entire in vitro diagnostics chain, from fermentation and enzyme production, to the manufacture of liquid reagents, the design and building of world-class diagnostic devices and the distribution of rapid test kits for infectious diseases and pregnancy. The EKF range of analysers are a trusted brand in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for the measurement of glucose, lactate, haemoglobin, haematocrit and HbA1c.
The EKF Diagnostics Group has distributors in more than 100 locations around the globe. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.
EKF Diagnostics Holdings plc includes wholly owned subsidiaries including Quotient Diagnostics Limited, Argutus Medical and Stanbio Laboratory. Stanbio Laboratory (Boerne, Texas) is a fifty year old business with a heritage in clinical chemistry. It was acquired in June 2011 as part of EKF’s strategy to grow its presence in North, Central and South America.